Skip to content

A Randomized, Single-Blinded, Parallel-Group, Regimen-Controlled, Prospective study of Glucosamine Sulfate Capsules with concurrent or sequential Sodium Hyaluronate Injection in treatment of Osteoarthritis

A Randomized, Single-Blinded, Parallel-Group, Regimen-Controlled, Prospective study of Glucosamine Sulfate Capsules with concurrent or sequential Sodium Hyaluronate Injection in treatment of Osteoarthritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009751
Enrollment
Unknown
Registered
2016-11-06
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis,OA

Interventions

Synchronization group:Judging by the researcher
Sequential group:Judging by the researcher

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-75 years old male or female; 2. In accordance with knee osteoarthritis (OA) diagnostic criteria; 3. X-ray Kellgren - Lawrence class for 1-3 (on both sides of the joints involved aiming at more serious side joints); 4. WOMAC (Likert type) pain score more than 6 cent; 5. The efficacy of non-drug therapy and simple poor analgesic; 6. Voluntary and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) The knee pain of other inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, gout, tumor, villonodular synovitis, joint trauma, suppurative arthritis, tuberculosis arthritis; (2) The serious gastrointestinal diseases, such as gastrointestinal ulcers, gastrointestinal bleeding, ulcerative colitis, Crohn's syndrome, acute pancreatitis, etc; (3) Serious cardiovascular, cerebrovascular, blood system, liver, kidney diseases, diabetic patients; (4) Mental illness or mental retardation can not correctly describe their own feelings; (5) Systemic infection or patients with infectious diseases treatment period; (6) Screening conducted joint cavity within three months before treatment, including joint cavity medicine injection and articular cavity cleaning and arthroscopic surgery, etc. (7) To participate in other clinical trials of similar drugs in the first 3 months; (8) The drug is being treated for osteoarthritis and the drug has a half-life of more than 35 hours; (9) In the first 6 months, the site has trauma or surgery, or the site has 3 or more trauma or surgical history; (10) Knee osteoarthritis, joint space narrow obviously, patients with operation indications; (11) Knee joint anatomical abnormalities of patients; (12) On research with drugs (amino glucose, sodium hyaluronate) and similar drug allergies; (13) Pregnant women, nursing mothers, or perhaps the pregnancy women; (14) Unable or unwilling to provide informed consent or poor compliance of patients; (15) Researchers think that should not be in the study of other reasons.

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities;Lequesne;

Countries

China

Contacts

Public ContactJia Xuewen

Ningbo First Hospital

13586948136@139.com+86 13586948136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026